DeutschNewstral
Article
thedailyrecord.com on 2018-02-28 16:39
Viela Bio spins out of MedImmune with signficant financing
Related news
Viela Bio officially goes publicbizjournals.com- Gaithersburg’s Viela Bio strikes $220M deal with Chinese drug companybizjournals.com
- Viela Bio clears another hurdle to get rare disease drug to marketbizjournals.com
- New MedImmune collaboration to target diabetes, obesitybizjournals.com
- Best Week, Worst Week: Viela Bio gets $250M and a green light; Gun-rights advocates on the defensivethedailyrecord.com
- MedImmune, NIST announce 5-year partnership for biological drug researchbizjournals.com
- KGlobal Neuromyelitis Optica Treatment Market Potential Growth, Share, Demand and Analysis Of Key Players-AstraZeneca, Teva Pharmaceutical Industries Ltd, Alexion Pharmaceuticals, Inc, Viela Bio, Anvil Biosciencesksusentinel.com
- AstraZeneca retires MedImmune brandbizjournals.com
- Best Week, Worst Week: Viela Bio files for $150M IPO; Md. officials called out over State Center maintenancethedailyrecord.com
- MedImmune, Tech Council of Maryland chart state's path to becoming a biotech hubbizjournals.com
- Venture equity firm spins out debt financing division to lend to software startupsbizjournals.com
- MViela Bio jumps 9% in trading debut before paring gainsmarketwatch.com
- Viela Bio receives FDA approval for autoimmune treatmentbizjournals.com
- Viela Bio to be acquired for $3.1 billionbizjournals.com
- Viela Bio partners with Chinese firm on rare diseasethedailyrecord.com
- Viela Bio teams with Japanese pharma firm, gets $30M paymentthedailyrecord.com